Tapewire

Nasdaq · USD

OPK

OPKO HEALTH, INC.

Export transactions ↓
Tapewire entity
4891
SEC CIK
0000944809
Parsed reports
659

Last 12 months

Inside the activity.

33 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 2025320
Dec 202500
Jan 202600
Feb 202600
Mar 202610
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 6,168 $1.77 $10,917.36
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,941,894

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 23,264 $1.76 $40,944.64
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,935,726

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 1,850 $1.76 $3,251.38
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,912,462

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,918 $1.76 $6,876.09
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,910,612

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 47,050 $1.75 $82,337.50
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,906,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 1,450 $1.75 $2,530.25
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,859,644

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2023 Filed Aug 18, 2023 11:10 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 1,500 $1.74 $2,602.50
Disclosure

SEC source: 0001209191-23-046474 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,858,194

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 11:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,923 $1.76 $6,904.48
Disclosure

SEC source: 0001209191-23-045764 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,856,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 11:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,900 $1.76 $6,844.50
Disclosure

SEC source: 0001209191-23-045764 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,852,771

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 11:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 57,358 $1.75 $100,376.50
Disclosure

SEC source: 0001209191-23-045764 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,848,871

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 14, 2023 Filed Aug 15, 2023 11:05 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 9,819 $1.75 $17,134.16
Disclosure

SEC source: 0001209191-23-045764 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,791,513

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 13,811 $1.83 $25,274.13
Disclosure

SEC source: 0001209191-23-045261 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,781,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 6,389 $1.83 $11,659.93
Disclosure

SEC source: 0001209191-23-045261 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,767,883

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 27,800 $1.82 $50,596.00
Disclosure

SEC source: 0001209191-23-045261 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,761,494

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 25,752 $1.82 $46,739.88
Disclosure

SEC source: 0001209191-23-045261 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,733,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 20,843 $1.81 $37,725.83
Disclosure

SEC source: 0001209191-23-045261 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,707,942

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 09, 2023 Filed Aug 10, 2023 10:59 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 5,405 $1.81 $9,756.03
Disclosure

SEC source: 0001209191-23-045261 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,687,099

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 25,768 $1.86 $47,928.48
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 16

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,681,694

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 21,432 $1.86 $39,756.36
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 15

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,655,926

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 160,243 $1.85 $296,449.55
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 14

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,634,494

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 9,100 $1.85 $16,825.90
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 13

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,474,251

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 45,527 $1.85 $83,997.32
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 12

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,465,151

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 100 $1.84 $184.25
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 11

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,419,624

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 70,000 $1.84 $128,800.00
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 10

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,419,524

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 33,564 $1.84 $61,589.94
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 9

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,349,524

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 500 $1.83 $916.25
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 8

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,315,960

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 177,580 $1.83 $324,971.40
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 7

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,315,460

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 4,530 $1.83 $8,285.37
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 6

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,137,880

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 54,271 $1.83 $99,044.58
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 5

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,133,350

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 3,400 $1.82 $6,196.50
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 4

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,079,079

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 43,885 $1.82 $79,870.70
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 3

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,075,679

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
August 07, 2023 Filed Aug 8, 2023 11:07 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
PurchaseCommon Stock 100 $1.82 $181.50
Disclosure

SEC source: 0001209191-23-044893 · doc4.xml · nonDerivative · entry 2

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

Frost Gamma Investments Trust · CIK 0001380896 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 200,031,794

F1 · ownership.nature: The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:18 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039368 · doc4.xml · derivative · entry 1

Yu Alice Lin-Tsing · CIK 0001462564 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:17 UTC GrantStock Option (Right to Buy) · Derivative 60,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039363 · doc4.xml · derivative · entry 1

PFENNIGER RICHARD C JR · CIK 0001200796 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2033-06-21

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:16 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039356 · doc4.xml · derivative · entry 1

PAGANELLI JOHN A · CIK 0001236687 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:15 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039346 · doc4.xml · derivative · entry 1

MEDEL ROGER MD · CIK 0001093125 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:14 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039343 · doc4.xml · derivative · entry 1

Lachman Prem A · CIK 0001847885 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:13 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039339 · doc4.xml · derivative · entry 1

KRASNO RICHARD M · CIK 0001215060 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

Read SEC document
June 22, 2023 Filed Jun 23, 2023 20:12 UTC GrantStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001209191-23-039337 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

Read SEC document
May 18, 2023 Filed May 19, 2023 20:40 UTC
FROST PHILLIP MD ET ALDirector · CEO & Chairman · 10% owner
GrantStock Option (Right to Buy) · Derivative 800,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-23-031038 · doc4.xml · derivative · entry 1

FROST PHILLIP MD ET AL · CIK 0000898860 · Director · CEO & Chairman · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:39 UTC
HSIAO JANE PH DDirector · Vice Chairman & CTO
GrantStock Option (Right to Buy) · Derivative 800,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-23-031036 · doc4.xml · derivative · entry 1

HSIAO JANE PH D · CIK 0001188834 · Director · Vice Chairman & CTO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:37 UTC
Rubin Steven DDirector · Executive VP-Administration
GrantStock Option (Right to Buy) · Derivative 700,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-23-031034 · doc4.xml · derivative · entry 1

Rubin Steven D · CIK 0001381874 · Director · Executive VP-Administration

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:38 UTC
Zerhouni Elias A.Director · Vice Chairman and President
GrantStock Option (Right to Buy) · Derivative 800,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-23-031035 · doc4.xml · derivative · entry 1

Zerhouni Elias A. · CIK 0001478398 · Director · Vice Chairman and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:36 UTC
Logal AdamSr. Vice President, CFO
GrantStock Option (Right to Buy) · Derivative 700,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-23-031032 · doc4.xml · derivative · entry 1

Logal Adam · CIK 0001356197 · Sr. Vice President, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:36 UTC
Nabel Gary J.Director · Chief Innovation Officer
GrantStock Option (Right to Buy) · Derivative 700,000 $0.00 Strike: $1.58 $0.00
Disclosure

SEC source: 0001209191-23-031030 · doc4.xml · derivative · entry 1

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024.

Read SEC document
May 05, 2023 Filed May 8, 2023 11:03 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 54,054 $1.85 $99,999.90
Disclosure

SEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 14

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 242,747

F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 05, 2023 Filed May 8, 2023 11:03 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 20,009 $1.85 $36,960.62
Disclosure

SEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 13

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 188,693

F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 05, 2023 Filed May 8, 2023 11:03 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 54,346 $1.84 $99,991.21
Disclosure

SEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 12

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 168,684

F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 05, 2023 Filed May 8, 2023 11:03 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 34,338 $1.84 $63,113.24
Disclosure

SEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 11

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 114,338

F3 · ownership.nature: Shares held by the Nabel Family Investments LLC, of which the Reporting Person is the manager with sole investment power and has an approximately 48% interest through the parent trust, the 2009 Nabel Family Children's Trust of which the Reporting Person has sole control, and sole investment power. The Reporting Per disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
May 05, 2023 Filed May 8, 2023 11:03 UTC
Nabel Gary J.Director · Chief Innovation Officer
PurchaseCommon Stock 54,945 $1.82 $99,999.90
Disclosure

SEC source: 0001209191-23-027852 · doc4.xml · nonDerivative · entry 10

Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 19,912,459

F2 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.